Market Access: Pharma

Mock Negotiations and Payer Consultations

Full-service solutions tailored to your needs

Alira Health provides a range of mock negotiation and payer consultation solutions to deliver commercial success, including:
  • Generation of integrated payer evidence and analyses plans to support market access and P&R
  • Preparation and facilitation of international payer-expert advisory boards to optimize development programs and gather insights on product value and evidence requirements
  • Design and facilitation of product value workshops with cross-functional and international teams
  • Payer/Health Technology Assessment (HTA) landscape assessments

Why choose Alira Health?

As your partner, we’ll work closely with you to uncover opportunities across the pharma industry, accelerate innovation, and deliver tomorrow’s standard of care. You’ll benefit from our:

  • Access to a diverse

    integrated team with deep industry expertise

  • Close collaboration

    with our regulatory and clinical

  • Specific, local insights

    as part of your larger, global strategy—a benefit of having market access teams in both the EU and U.S.

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Jean-François Ricci
Jean-François Ricci
Executive Vice President, Global Market Access
Our strong client partnerships allow us to deliver in-depth, customized strategies and access solutions—all designed to maximize product value across its full lifecycle.

Related News

News February 7, 2024
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Pharma Transaction Advisory
News January 26, 2024
Alira Health’s CDD Supports Alcami Acquisition of Pacific Pharmaceutical Services
We are pleased to have been an advisor on Alcami’s acquisition of Pacific Pharmaceutical Services (PPS). Alira Health advised Alcami, a leading Contract Development Manufacturing(...)
CDD CDMO Pharma
Events January 22, 2024
Pharmapack Europe
Connect with our Drug Delivery Systems and CDMO experts Aude Ouensanga, Giulia Valsecchi, and Michal Raciborski on site at Pharmapack Europe.
CDMO Drug Delivery Pharma
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
Case Studies January 8, 2024
Pharma Company Extends to New Markets through Strategic Licensing Agreements
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
Market Access Pharma
Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Blog November 2, 2023
The Impact of New Treatment Approvals in Oncology on Relative Survival Rates for EU Patients
This article explores the relationship between the number of new cancer treatment approvals and the five-year relative survival of cancer patients across the European Union (EU).
Oncology Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.